From HCV To HBV Cure
- 3 January 2017
- journal article
- review article
- Published by Wiley in Liver International
- Vol. 37, 73-80
- https://doi.org/10.1111/liv.13324
Abstract
Approximately 170 million people are chronically infected with HCV and 350 million are chronically infected with HBV worldwide. It is estimated that more than one million patients die from complications related to chronic viral hepatitis, mainly HCC which is one of the most frequent cancers in many countries, especially Africa, the Middle East and Asia. HCV drug development has been impressive, and this revolution led to several direct-acting antiviral agents achieving an HCV cure after only 6-12 weeks. This progress could theorically lead to HCV global elimination making HCV and its consequences a rarity. HBV research and development programs can learn from the HCV experience, to achieve an HBV functional or sterilizing cure. This review will summarize key steps which have been realized for an HCV cure, and discuss the next steps to achieve for an HCV elimination. And also, how this HCV revolution has inspired scientists and clinicians to achieve the same for HBV.Keywords
Funding Information
- NIH CFAR (P30-AI050409)
This publication has 58 references indexed in Scilit:
- Hepatitis B surface antigen serum level is associated with fibrosis severity in treatment-naïve, e antigen-positive patientsJournal of Hepatology, 2013
- Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up studyThe Lancet, 2013
- Identification of Disubstituted Sulfonamide Compounds as Specific Inhibitors of Hepatitis B Virus Covalently Closed Circular DNA FormationAntimicrobial Agents and Chemotherapy, 2012
- Prediction of off-Treatment Response to Lamivudine by Serum Hepatitis B Surface Antigen Quantification in Hepatitis B E Antigen-Negative PatientsAntiviral Therapy, 2011
- The NS5A Replication Complex Inhibitors: Difference Makers?Clinics in Liver Disease, 2011
- Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: A European perspectiveJournal of Hepatology, 2010
- Early serum HBsAg drop: A strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patientsHepatology, 2008
- Characterization of the Intracellular Deproteinized Relaxed Circular DNA of Hepatitis B Virus: an Intermediate of Covalently Closed Circular DNA FormationJournal of Virology, 2007
- Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapyGastroenterology, 2004
- Hepatitis B VaccineThe New England Journal of Medicine, 1980